Drug intelligence / Profile preview

ENC-201

Development stage: Unknown
Lead developer: Encellin
Modality: Cell Therapies
Administration: Implant

Overview

ENC-201 is Encellin's lead candidate, an Encapsulated Cell Replacement Therapy (EnCRT) designed for the treatment of Type 1 Diabetes. It consists of primary islets encapsulated within a proprietary device that protects these therapeutic cells from the body's immune system. This allows the encapsulated islets to function as a "living medicine," providing long-term therapeutic benefits, such as insulin production and glucose regulation, from a single implant. The technology originated from research conducted at the UCSF Desai lab.

Other names: ENC-201-CED hPIENC201-CED hPIENC 201-CED hPI

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on ENC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENC-201.

Explore the full profile